Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancer
Phase 2
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000002570
- Lead Sponsor
- ational Hospital Organization Nagoya Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
1. Contraindication for amrubicin 2. Carcinomatous pleuritis, pericarditis, peritonitis and other metastasis with local therapy indication 3. Patient can not enroll during radiotherapy, but can be registered after interval (chest: four weeks; without chest: one weeks). 4. Serious medical complication: Uncontrolled angina pectoris, myocardial infarction for less than 3 months, patient with cardiac failure. Uncontrolled diabetes mellitus, hypertension. 5. Infected patients 6. Other clinical difficulties in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method